Interventions for American cutaneous and mucocutaneous leishmaniasis

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  González, Urbà ^a   Pinart, Mariona ^a   Rengifo Pardo, Mónica ^b   Macaya, Antonio ^c   Alvar, Jorge ^d   Tweed, John A ^b  

^a HOSPITAL PLATÓ   (Spain)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALKALINE PHOSPHATASE; ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIPROTOZOAL AGENT; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; CREATININE; DICLOXACILLIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; KETOCONAZOLE; LEISHMANIA MEXICANA VACCINE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; METHYLBENZETHONIUM CHLORIDE PLUS PAROMOMYCIN; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PENTOXIFYLLINE; PLACEBO; PROBENECID; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG; WR 279396;

ABDOMINAL PAIN; ADJUVANT THERAPY; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY; APPLICATION SITE BURNING; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTHRALGIA; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACTERIAL INFECTION; BONE PAIN; BURN; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CELLULITIS; CHILL; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; COLIC; CONTINUOUS INFUSION; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DATA EXTRACTION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ECG ABNORMALITY; EMBASE; EOSINOPHILIA; EPIGASTRIC PAIN; ERYTHEMA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE PRURITUS; INJECTION SITE REACTION; JOINT STIFFNESS; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIA PANAMENSIS; LEISHMANIN SKIN TEST; LEUKOPENIA; LOW DRUG DOSE; MALAISE; MEDLINE; META ANALYSIS; MICROBIOLOGICAL EXAMINATION; MOTION SICKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NECROSIS; NEUROLOGIC DISEASE; PAIN; PARESTHESIA; PHLEBITIS; PRURITUS; QT INTERVAL; QUALITY CONTROL; RASH; RELAPSE; REMISSION; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; SKIN LEISHMANIASIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TOXIC HEPATITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ULCER; VOMITING; WEAKNESS;

EID: 70349088254     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004834.pub2     Document Type: Review

References (145)

1. Almeida R, D'Oliveira A Jr, Machado P, Bacellar O, Ko AI, de Jesus AR, et al.Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. Journal of Infectious Diseases 1999;180:1735-1737. (Pubitemid 29506486)
2. Andersen EM, Cruz-Saldarriaga M, LLanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verasategui C, et al.Comparison of meglumine and pentamidine for peruvian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 2005;72(2):133-137. (Pubitemid 41278895)
3. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without Interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clinical Infectious Diseases 1994;18:381-384. (Pubitemid 24086308)
4. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leish-maniasis with the paromomycin plus methylbenzethonium chloride ointment in Guatemala. The American Journal of Tropical Medicine and Hygiene 2001;65(5):466-470. (Pubitemid 33134578)
5. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Tropica 2004;91:153-160. (Pubitemid 38952716)
6. Arevalo I, Tulliano G, Quispe A, Spaeth G, Mathlashewski, LLanoscuantas A, et al.Role of imiquimod and parenteral meglumine antimoniate in the intitial treatment of cutaneous lesihmaniasis. CID 2007;44:1549-1554. (Pubitemid 46871500)
7. Ballou WR, McClain JB, Gordon DM, Dhanks GD, Adujar J, Berman JD, et al.Safety and efficacy of high-dose sodium stibogluconate therapy of american cutaneous leishmaniasis. Lancet 1987;4 (8549):13-16.
8. Convit J, Castellanos PL, Rondon A, Pinardi ME, Ulrich M, Castes M, et al.Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987;21:401-404. (Pubitemid 17016578)
9. Convit J, Castellanos PL, Ulrich M, Castés M, Rondón A, Pinardi ME, et al.Immunotherapy of localized, intermediate, and diffuse forms of american cutaneous leishmaniasis. Journal of Infectious Diseases 1989;160:104-114. (Pubitemid 19162999)
10. Correia D, Macêdo VO, Carvalho EM, Barral A, Magalhâes AV, de Abreu MVA, et al.Comparative study of meglumine antimoniate, pentamidine isothionate and aminosidine sulphate in the treatment of primary skin lesions caused by Leishmania (viannia) braziliensis. Revista da Sociedade Brasilera de Medicina Tropical 1996;29(5):447-453. (Pubitemid 26300355)
11. D'Oliveira A Jr, Machado PR, Carvalho EM. Evaluating the efficacy of allopurinol for treatment of cutaneous leishmaniasis. International Journal of Dermatology 1997;36(12):938-940. (Pubitemid 28053898)
12. Figueiredo Kopke LF, Siviero do Vale EC, Grossi Araujo M, Araújo Magalhâes P, Furtado T. Treatment of American Tegumentary Leish-maniasis with N-methyl-glucamine: double-blind study with doses of 14 mg/kg/day and 28 mg/kg/day of antimoniate [Tratamento da leishmaniose tegumentar americana pelo antimoniato de N-metil-glucamina: Estudo duplo-cego com doses de 14 mg/kg/dia e 28 mg/kg/dia de antimônio]. Anais Brasileiros de Dermatologia 1991;66 (2):87-94.
13. Franke ED, LLanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, et al.Efficacy of 28-day and 40-day regimens of sodium stibogluconate (pentostam) in the treatment of mucosal leishmaniasis. The American Journal of Tropical Medicine and Hygiene 1994;51 (1):77-82. (Pubitemid 24266291)
14. Guderian RH, Chico ME, Rogers MD, Pattishall KM, Grogl M, Berman JD. Placebo controlled treatment of ecuadorian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 1991;45(1):92-97.
15. Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of american cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88:700-703.
16. Llanos-Cuentas A, Echevarria J, Cruz M, La Rosa A, Campos P, Campos M, et al.Efficacy of sodiumstibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clinical Infectious Diseases 1997;25:677-684. (Pubitemid 27392612)
17. Llanos-Cuentas A, Echevarria J, Seas C, Chang E, Cruz M, Alvarez E, et al.Parenteral aminosidine is not effective for peruvian mucocutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 2007;76(6):1128-1131. (Pubitemid 351837878)
18. Lobo IMF, Soares MBP, Correia TM, de Freitas LAR, Oliveira MI, Nakatani M, et al.Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006;100:642-649.
19. Miranda-Verástegui C, LLanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clinical Infectious Diseases 2005;40:1395-1403. (Pubitemid 40628625)
20. Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, et al.Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clinical Infectious Diseases 2007;44:788-793. (Pubitemid 46365302)
21. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, et al.Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. International Journal of Dermatology 2002;41(2):73-78. (Pubitemid 34552351)
22. Martinez S, Marr J. Allopurinol in the treatment of american cutaneous leishmaniasis. The New England Journal of Medicine 1992; 326:741-744.
23. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clinical Infectious Diseases 1997;24:165-169. (Pubitemid 27081538)
24. Navin TR, Arana BA, Arana FE, deMérida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimoniate (glucantime) versus localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. The American Journal of Tropical Medicine and Hygiene 1990;42(1):43-50 (89-153).
25. Navin TR, Aran BA, Arana FE, Berman JD, Chajón JF. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Diseases 1992;165:528-534.
26. Neva FA, Ponce C, Ponce E, Kreutzer R, Modabber F, Olliaro P. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Transactions of the Royal Society of Tropical Medicine and Hygiene 1997;91:473-475. (Pubitemid 27421247)
27. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C. Treatment of american cutaneous leishmaniasis: a comparison between low dosage (5mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathologie et Biologie 1997;45(6): 496-499. (Pubitemid 27306145)
28. Oster CN, Chulay JD, Hendricks LD, Pamplin III CL, Ballou WR, Berman JD, et al.American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. The American Journal of Tropical Medicine and Hygiene 1985;34(5):856-860.
29. Palacios R, Osorio LE, Grajales LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to leishmania viannia species. The American Journal of Tropical Medicine and Hygiene 2001;64(3, 4):187-193. (Pubitemid 32565849)
30. Saenz RE, Paz HM, Johnson CM, Narvaez E, de Vasquez AM. Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis [Evaluación de la effectividad y toxicidad del pentostam y del glucantime en el tratamiento de la leishmaniasis cutanea]. Revista Médica de Panamá 1987;12: 148-157.
31. Saenz RE, Paz H. Efficacy of ketoconazole against leishmania braziliensis panamensis cutaneous leishmaniasis. The American Journal of Medicine 1990;89:147-155. (Pubitemid 20254438)
32. Santos JB, de Jesus AR, Machado PR, Magalhâes A, Salgado K, Carvalho EM, et al.Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. Journal of Infectious Diseases 2004;190:1793-1796. (Pubitemid 39487824)
33. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for colombian cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88:695-698.
34. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimoniate as treatment for american cutaneous leishmaniasis: controlled study. Clinical Infectious Diseases 1998;26:56-58. (Pubitemid 28068155)
35. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, et al.Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. The American Journal of Tropical Medicine and Hygiene 2002;66(2):147-151. (Pubitemid 34755645)
36. Soto J, Valda-Rodriguez L, Toledo J, Vera-Navarro L, Luz M, Monasterios-Torrico H, et al.Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 2004;71(5): 577-581. (Pubitemid 39601154)
37. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al.Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 2004;38:1266-1272. (Pubitemid 38608569)
38. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, et al.Inefficacy of allopurinol as monotherapy for colombian cutaneous leishmaniasis: a randomized, controlled trial. Annals of Internal Medicine 1997;126(3):232-236. (Pubitemid 27061579)
39. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogeneicity, and efficacy of an autoclaved leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004;22:1320-1326. (Pubitemid 38296677)
40. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, et al.Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 1999;17:1179-1185. (Pubitemid 29132952)
41. De Luca PM, Mayrink W, Pinto JA, Coutinho SG, Santiago MA, Toledo VP, et al.A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Tropica 2001;80(3):251-260. (Pubitemid 33043971)
42. De Luca PM, Mayrink W, Santiago MA, Nogueira R, Conceição- Silva F, Mélo G, et al.Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test. Transactions of the Royal Society of Tropical Medicine and Hygiene 2003;97 (6):709-712. (Pubitemid 41051084)
43. Deps PD, Viana MC, Falqueto A, Dietze R. Evaluation of the efficacy and toxicity of N-methyl-glucantime vs BP88 Sodium Stibogluconate in the treatment of localized cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 2000;33(6):535-543. (Pubitemid 32108388)
44. Fagundes A, Marzochi MCA, Perez M, Schubach A, Ferreira A, Silva JP, et al.Skin reactivity to thimerosal and phenol-preserved Montenegro antigen in Brazil. Acta Tropica 2007;101:25-30. (Pubitemid 46206066)
45. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC. Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88:453-455. (Pubitemid 24264547)
46. Laguna-Torres VA, Silva CAC, Correia D, Carvalho EM, Magalhâes AV, de Oliveira Macêdo V. Efficacy of mefloquine in the treatment of skin leishmaniasis in an endemic area of leishmania (viannia) braziliensis. Revista da Sociedade Brasileira de Medicina Tropical 1999; 32(5):529-532. (Pubitemid 29526793)
47. Llanos A, Cieza J, Bernanrdo J, Echevarria J, Biaggioni I, Sabra R, et al.Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney International 1991;40:302-308.
48. Monjour L, Neogy AB, Vouldoukis I, Silva OA, Boisnic S, Brito ME, et al.Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil. Memórias do Instituto Oswaldo Cruz 1994;89(3):479-483.
49. Nascimento E, Mayrink W, da Costa CA, Michalick MSM, Melo MN, Barros GC, et al.Vaccination of humans against cutaneous leishmaniasis: cellular and humoral inmune responses. Infection and Immunity 1990;58(7):2198-2203. (Pubitemid 20212296)
50. Oliveira-Neto MP, Mattos M, Primez C, Fernandes O, Gonçalves- Costa SC, Souza CF, et al.Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucantime in Rio de Janeiro, Brazil. Revista do Instituto de Medicina Tropical de São Paulo 2000;42(6): 321-325. (Pubitemid 32057363)
51. Rodriguez LV, Dedet JP, Paredes V, Mendoza C, Cardenas F. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Memorias do Instituto Oswaldo Cruz 1995;90(4):525-528.
52. Saldanha AC, Romero GA, Guerra C, Merchan-Hamann E, Macedo Vde O. Comparative study between sodium stibogluconate BP 88 and meglumine antimoniate in cutaneous leishmaniasis treatment. II. Biochemical and cardiac toxicity. Revista da Sociedade Brasileira de Medicina Tropical 2000;33(4):383-388. (Pubitemid 30604786)
53. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clinical Infectious Diseases 1993;16:417-425. (Pubitemid 23066954)
54. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of colombian cutaneous leishmaniasis with four injections of pentamidine. The American Journal of Tropical Medicine and Hygiene 1994;50(1): 107-111. (Pubitemid 24059993)
55. Velez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CMF, et al.Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005;99:593-598. (Pubitemid 40823865)
56. Wortmann G, Scoot Miller R, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clinical Infectious Diseases 2002;35:261-267. (Pubitemid 34800273)
57. Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, et al.A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. The American Journal of Tropical Medicine and Hygiene 2007;77(4):640-646. (Pubitemid 351844285)
58. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, et al.Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 2008;78(2):210-211. (Pubitemid 351844550)
59. Maguire JH. Phase II Randomized Study of Allopurinol Versus Glucantime Versus Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil. ClinicalTrials.gov 1995.
60. Llanos Cuentas A. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis. ClinicalTrials.gov 2004.
61. Nascimento E, Piazza FM. Randomized, Double-Blind, Adjuvant and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis. ClinicalTrials.gov 2004.
62. Piazza FM. A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f +MPL-SEVaccine Compared to the Leish-111f Protein Alone in Montenegro Skin Test-Negative Healthy Adults. ClinicalTrials.gov 2005.
63. Soto J. Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia. ClinicalTrials.gov 2005.
64. Llanos-Cuentas A. Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients. ClinicalTrials.gov 2005.
65. Silva SY, Rueda LC, Lopez M, Velez ID, Rueda-Clausen CF, Smith DJ, et al.Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]. Trials 2006;15(7):14. (Pubitemid 44164734)
66. Romero GS. Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis. ClinicalTrials. gov 2006.
67. Carvalho EM, Marshall JG. Empiric Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Trial in Subjects Co-Infected With Helminths and Leishmania Brasiliensis. ClinicalTrials.gov 2007.
68. Lopez L. Phase 3 Open-Label Study of Efficacy and Safety of Miltefosine vs Glucantime for Cutaneous Leishmaniasis in Colombia.. ClinicalTrials.gov 2006.
69. Miranda MC, Rodriguez I. Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia. ClinicalTrials.gov 2007.
70. Soto J, Toledo J. Efficacy and safety of a short course of the combination of miltefosine and antimony to treat cutaneous leishmaniasis in Bolivia. ClinicalTrials.gov 2007.
71. Machado PRL. Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control. ClinicalTrials.gov 2008.
72. Rabello A, Pedras M. Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis. ClinicalTrials.gov 2008.
73. Al-Zamel F, Al-Shammary FJ, El-Shewemi S, Soliman R. Enhancement of leishmanicidal activity of humanmacrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralblatt für Bakteriologie : international journal of medical microbiology 1996;285(1):92-105. (Pubitemid 27005637)
74. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends in Parasitology 2006;22(12):552-557.
75. Alvar J, Aparicio P, Aseffa A, den Boer M, Cañavate C, Dedet JP, et al.The Relationship between Leishmaniasis and AIDS: The Second 10 Years.. Clinical Microbiology Review 2008;2:334-359. (Pubitemid 351555511)
76. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA. Treatment of mucosal leishmaniasis in Latin America: systematic review. The American Journal of Tropical Medicine and Hygiene 2007;77(2): 266-274.
77. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al.Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America 2001;33(11):1847-1851. (Pubitemid 33105123)
78. Asilian A, Sharif A, Faghihi G, Enshaeieh Sh, Shariati F, Siadat AH. Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 2004;43:736-738. (Pubitemid 39405857)
79. Aviles H, Belli A, Armijos R, Monroy FP, Harris E. Detection and identification of Leishmania parasites in clinical specimens in Ecuador: A comparison with classical diagnostic methods. Journal of Parasitology 1999;85:181-187. (Pubitemid 29251830)
80. Babajev KB, Babajev OG, Korepanov VI. Treatment of cutaneous leishmaniasis using a carbon dioxide laser. Bulletin of the World Health Organization 1991;69:103-106.
81. Badaro R, Lobo I, Munos A, Netto EM, Modabber F, Campos-Neto A, et al.Immunotherapy for drug-refractory mucosal leishmaniasis. The Journal of Infectious Diseases 2006;194(8):1151-1159.
82. Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. The Journal of Burn Care & Rehabilitation 1995;16(5):535-538.
83. Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within monocyte-derived macrophages in vitro. The American Journal of Tropical Medicine and Hygiene 1981; 30:318-321.
84. Berman JD. Treatment of New World cutaneous and mucosal leishmaniases. Clinics in Dermatology 1996;14(5):519-522. (Pubitemid 26327746)
85. Berman J. Miltefosine to treatment leishmaniasis: drug evaluation. Expert Opinion on Investigational drugs 2005;6(8):1381-1388.
86. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, et al.Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases 2006;43(7):917-924. (Pubitemid 44435523)
87. Brandao-Filho SP, Campbell-Lendrum D, Brito M, Shaw J, Davies C. Epidemiological surveys confirm an increasing burden of cutaneous leishmaniasis in north-east Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999;93:488-494. (Pubitemid 29495829)
88. Bigby M, Williams H. Appraising Systematic Reviews and Meta-analyses. Archives of Dermatology 2003;139:795-798.
89. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al.Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nature reviews. Microbiology 2007;5(11):873-882. (Pubitemid 47578388)
90. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends in parasitology 2003;19(11):502-508.
91. Croft SL, Seifert K, Yardley V. Current scenario of drug development for Leishmaniasis. The Indian Journal of Medical Research 2006;123 (3):399-410. (Pubitemid 43905578)
92. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries.. Cadernos de saúde pública / Ministério da Saúde, Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública 2000;16(4):925-950.
93. Desjeux P. Leishmaniasis: public health aspects and control. Clinical Dermatology 1996;14:417-423. (Pubitemid 26327735)
94. Dimier-David L, David C, Ravisse P, Bustillos R, Revollo S, Lyevre P, et al.Parasitological diagnosis of mucocutaneous leishmaniasis due to Leishmania braziliensis in Bolivia. Revista da Sociedade Brasileira de Medicina Tropical 1991;24:231-234.
95. Escobar MA, Smith DS, Palma GI. American cutaneous and mucocutaneous leishmaniasis (tegumentary): A diagnostic challenge. Tropical Doctor 1992;22 Suppl 1:69-78.
96. Falcoff E, Taranto NJ, Remondegui CE, Dedet JP, Canini LM, Ripoll CM, et al.Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994;88 (1):95-97. (Pubitemid 124018643)
97. Flynn B, Wang V, Sacks DL, Seder RA, Verthelyi D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxy nucleotides expressing CpG motifs. Infection and Immunity 2005;73(8):4948-4954. (Pubitemid 41105652)
98. Ghanem BM, el-Shazly AM, Fawzy M, Arafa MA, Morsy TA. Allopurinol in the treatment of zoonotic cutaneous leishmaniasis. Journal of the Egyptian Society of Parasitology 1996;26(3):619-628.
99. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. British Medical Journal 2007;334(7589):349-351.
100. González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: %3Chtml%3E%3Cbody id=%22body%22%3ECD005067%3C/body%3E%3C/html%3E]
101. Gonçalves GS, Fernandes AP, Souza RC, Cardoso JE, de Oliveira- Silva F, Maciel FC, et al.Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Tropica 2005;93(2):161-167.
102. Goodman AC. Beware the "Texas sharp shooter" in rate ratios of progression. British Medical Journal 2007;334(7591):440.
103. Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. The Journal of Parasitology 1999;85(2):354-359. (Pubitemid 29251857)
104. Hepburn NC. Management of cutaneous leishmaniasis. Current Opinion in Infectious Diseases 2001;14:151-154.
105. Herwaldt B. Leishmaniasis. Lancet 1999;354:1191-1199.
106. Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, Singh IJ, et al.Randomised controlled trial of aminosidine v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India - paromomycin. British Medical Journal 1998;316(7139):1200-1205. (Pubitemid 28171334)
107. Jolliffe DS. Cutaneous leishmaniasis from Belize--treatment with ketoconazole. Clinical and Experimental Dermatology 1986;11(1):62-68.
108. Junaid AJN. Treatment of cutaneous leishmaniasis with infrared heat. International Journal of Dermatology 1986;25:470-472. (Pubitemid 16025330)
109. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled trials. British Medical Journal 2001;323:42-46. (Pubitemid 32682008)
110. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, et al.Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. The American Journal of Tropical Medicine and Hygiene 2001;65(2):87-89. (Pubitemid 32746963)
111. Levine N. Cutaneous leishmaniasis treated with controlled localized heating. Archives of Dermatology 1992;128(6):759-761.
112. Machado-Coelho GL, Caiaffa WT, Genaro O, Magalhães PA, Mayrink W. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005;99(1):55-61. (Pubitemid 39517037)
113. Meawad OB. Selective heat therapy in cutaneous leishmaniasis: a preliminary experience using the 585 nm pulsed dye laser. Journal of the European Academy of Dermatology and Venereology 1997;8:241-244.
114. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Medicine and Infectious Disease 2007;5(3):150-158.
115. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biology and Disease 2006;6:3. (Pubitemid 46785019)
116. Mäntylä A, Garnier T, Rautio J, Nevalainen T, Vepsälainen J, Koskinen A, et al.Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. Journal of Medicinal Chemistry 2004;47(1):188-195. (Pubitemid 38040502)
117. Nelson DJ, LaFon SW, Tuttle JV, Miller WH, Miller RL, Krenitsky TA, et al.Allopurinol ribonucleoside as an antileishmanial agent. Biological effects, metabolism, and enzymatic phosphorylation. The Journal of Biological Chemistry 1979;254(22):11544-11549.
118. Neva FA, Petersen EA, Corsey R, Bogaert H, Martinez D. Observations on local heat treatment for cutaneous leishmaniasis Observations on local heat treatment for cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene 1984;33:800-804.
119. Passos VM, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Gontijo CM, et al.Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis features (1989-1995). Revista da Sociedade Brasileira de Medicina Tropical 2001;34(1):5-12.
120. Pirmez C, Da Silva-Trajano V, Paes-Oliveira M, Da Cruz AM, Gonolves-Da Costa SC, et al.Use of PCR in diagnosis of human American tegumentary leishmaniasis in Rio de Janeiro, Brazil. Journal of Clinical Microbiology 1999;37:1819-1823. (Pubitemid 29235229)
121. Ponte Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biology and Disease 2003;2(1):14.
122. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, et al.Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 2003; 36(1):65-69. (Pubitemid 36648215)
123. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. The Lancet Infectious Diseases 2007;7(9):581-596.
124. Remme JH, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP, et al.Strategic emphases for tropical diseases research: a TDR perspective. Trends in Parasitology 2002;18(10):421-426.
125. Remme JHF, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP, et al.Strategic emphases for tropical diseases research: a TDR prespective. Trends in Microbiology 2002;10(10):435-440.
126. Rodriguez ME, Inguanzo P, Ramos A, Perez J. Treatment of cutaneous leishmaniasis with CO2 laser radiation. Revista Cubana de Medicina Tropical 1990;42:197-202.
127. Romero GA, Lessa HA, Macêdo VO, Carvalho EM, Barral A, Magalhães AV, et al.Open therapeutic study with aminosidine sulfate in mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis. Revista da Sociedade Brasileira de Medicina Tropical 1996;29(6):557-565. (Pubitemid 26401551)
128. Sacks DL, Barral A, Neva F. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. The American Journal of Tropical Medicine and Hygiene 1983;32:300-304.
129. Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Revista da Sociedade Brasileira de Medicina Tropical 1997; 30(2):125-128.
130. Savioli L, Engels D, Daumerie D, Jannin J, Alvar J, Asiedu K, et al.Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization. PLoS medicine 2006;3(6):e283. (Pubitemid 43987841)
131. Seaton RA, Morrison J, Man I, Watson J, Nathwani D. Out-patient parenteral antimicrobial therapy--a viable option for themanagement of cutaneous leishmaniasis. QJM : monthly journal of the Association of Physicians 1999;92(11):659-667. (Pubitemid 29515872)
132. Singh S, Sivakumar R. Challenges and new discoveries in the treatment of leishmaniasis. Journal of Infection and Chemotherapy : official journal of the Japan Society of Chemotherapy 2004;10(6):307-315. (Pubitemid 40142819)
133. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, et al.Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases 2004;38:1266-1272. (Pubitemid 38608569)
134. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in Indi. Bulletin of the World Health Organization 2005; 83(5):394-395. (Pubitemid 40704871)
135. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. The Indian Journal of Medical Research 2006;123(3): 345-352. (Pubitemid 43905574)
136. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis--a systematic review with ameta-analysis. International Journal of Dermatology 2008;109(2):109-124.
137. Uezato H, Hagiwara K, Hosokawa A, Maruno M, Nonaka S, Oshiro M, et al.Comparative studies of the detection rates of Leishmania parasites from formalin, ethanol-fixed, frozen human skin specimens by polymerase chain reaction and Southern blotting. Journal of Dermatology 1988;25:623-631.
138. Urcuyo FG, Zaias N. Oral ketoconazole in the treatment of cutaneous leishmaniasis. International Journal of Dermatology 1982;21:414-416. (Pubitemid 12062639)
139. Velasco-Castrejon O, Walton BC, Rivas-Sanchez B, Garcia MF, Lazaro GJ, Hobart O, et al.Treatment of cutaneous leishmaniasis with localized current field (radiofrequency) in Tabasco, Mexico. The American Journal of Tropical Medicine and Hygiene 1997;57(3):309-312. (Pubitemid 27407268)
140. Vaneau M, Chaby G, Guillot B, Martel P, Senet P, Téot L, et al.Consensus panel recommendations for chronic and acute wound dressings. Archives of Dermatolology 2007;143(10):1291-1924. (Pubitemid 47607682)
141. WHO. The leishmaniasis. World Health Organization Technical Report Service 1990;793:59-62.
142. World Health Organization. WHOReport on global surveillance of epidemic-prone infectious diseases. http://www.who.int/emc-documents/ surveillance/docs/whocdscsrisr2001.html/Leishmaniasis/Leishmaniasis.htm 2001; Vol.Date last accessed: 2/4/2004.
143. WHO. World Health Report 2002. http://www.who.int/whr/2002/annex/en/ 2002; Vol.Date last accesed: 2/4/2004.
144. World Heald Organisation. Control of leishmaniasis. Report by the Secretariat. http://ftp.who.int/gb/ebwha/pdf-files/WHA60/A60- 10-en.pdf 22 March 2007.
145. World Health Organization (WHO). Report of the Fifth Consultatve Meeting on HIV-Leishmania co-infection. Addis Ababa, 20 to 22 March 2007. WHO/CDS/NTD/IDM/2007 2008 (in press).